Clinical Affairs Committees

Clinical Affairs Committee

To monitor, develop and make recommendations to address issues related to infectious disease clinical practice; to monitor and make recommendations to address issues relating to the practice of hospital epidemiology and infection control; to monitor and advocate with Medicare and other third party payers appropriate coverage and reimbursement for infectious disease services; to develop and make recommendations on providing products and services to improve the practice efficiency of infectious disease clinicians; to identify and suggest clinicians to serve on other committees, task forces, work groups and panels convened to develop practice guidelines; and to make recommendations on activities/issues under its purview that involve federal legislation or regulation.

Hepatitis Task Force

To develop educational programs and resources to assist ID specialists in the treatment of hepatitis (e.g. program sessions for IDWeek, website content); to help facilitate IDSA participation in the development of practice guidelines in hepatitis; to promote federal policies that help foster an appropriate response to prevent and treat hepatitis; and to explore with the ID Training Program Directors Committee (IDTPDC) the possible development of teaching objectives and educational material for ID fellows.

Quality Improvement Work Group

The Quality Improvement Work Group advocates for valid and quantifiable performance measures that IDSA members can implement to improve patient care outcomes in infectious diseases. They also determine appropritae measure-topics that can be reportable across the discipline of ID.

State & Regional Societies Assembly Steering Committee

Value of Infectious Diseases Specialists Work Group 

To work in conjunction with a health services researcher to conduct an analysis (using claims and medical records data) to assess the value of infectious diseases specialists involvement in the care of patients with certain infectious diagnoses (including complications) and across the settings of care when transitions occur—possible diagnoses to examine as part this analysis include endocarditis, encephalitis, meningitis, ventilator-associated pneumonia, multi-drug resistant organisms, prosthetic joint infections, HIV/AIDS, and staphylococcus aureus bacteremia.  The study would ideally assess infectious diseases specialists’ impact on the cost and quality of patient care using risk-adjusted length of stay, episode costs, and 30 day readmission rates.